LABCORP HOLDINGS INC. reported revenue of $3.73B for the period ended 2026-06-30, +5.8% year on year. Net income was $0.30B, a 8.0% net margin on a 29.8% gross margin. The largest revenue line is Diagnostics at 78% of the total. Free cash flow for the period was $0.31B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $3.73B | +5.8% |
| Gross profit | $1.11B | — |
| Operating income | $0.45B | — |
| Net income | $0.30B | +25.6% |
| Gross margin | 29.8% | Net margin 8.0% |
| Revenue Q/Q | +5.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| Diagnostics | $2.90B | 77.7% |
| Biopharma Laboratory Services | $0.84B | 22.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $2.62B | 70.2% |
| SG&A | $0.58B | 15.5% |
| Tax & other | $0.15B | 4.1% |
| Item | Amount |
|---|---|
| Total assets | $18.53B |
| Total liabilities | $9.91B |
| Shareholders' equity | $8.61B |
| Equity / assets | 46.4% |
| Operating cash flow | $0.45B |
| Capital expenditure | $0.13B |
| Free cash flow | $0.31B |
| Cash conversion (OCF / net income) | 149% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
LRCX ・ LVS ・ LDOS ・ LEN ・ LII ・ LLY ・ LIN ・ LYV ・ LMT ・ L ・ LOW ・ LULU
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies